Oligonucleotide Therapeutics and Delivery Conference 2021
Evvnt Promotion / evvnt
Archiv
22.09.2021 - 23.09.2021 Online
Time: 09:00 - 17:30
Kongressthemen
Oligonucleotide therapeutics - the emerging medicine class - are harnessing the therapeutic benefit of targeting genetic material via antisense, mRNA, RNAi, saRNA and siRNA. Their market growth: CAGR of 13.7% projected to reach USD 8.2 billion by 2024 is driven by their potential to provide more efficacious and less toxic alternatives to small molecules. They bring about the ability to affect targets that have been considered "non-draggable".
Oligonucleotide therapeutics - the emerging medicine class - are harnessing the therapeutic benefit of targeting genetic material via antisense, mRNA, RNAi, saRNA and siRNA. Their market growth: CAGR of 13.7% projected to reach USD 8.2 billion by 2024 is driven by their potential to provide more efficacious and less toxic alternatives to small molecules. They bring about the ability to affect targets that have been considered "non-draggable".
Kongressorganizer (PCO)
SMI Group Limited
SMI Group Limited
Anfragen und Anmeldung:
https://go.evvnt.com/774501-0?pid=4832
Frau Jinna Sidhu
Allgemeinmedizin
Sprache
Englisch
Englisch
Kongressgebühr
Virtual attendance: GBP 999.00
Virtual attendance: GBP 999.00
Teilnehmer erwartet
150
150
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
83 Great Titchfield Street
W1W 6RH London
Großbritannien
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."
